Robust Immune Responses for Herpes Zoster Subunit Vaccine

MONDAY, May 21, 2018 -- Recipients of the herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01B Adjuvant System, develop robust immune responses, according to a study published in the June 1 issue...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Yamaoka K Abstract INTRODUCTION: Tofacitinib selectively inhibits the Janus kinases, intracellular tyrosine kinases that are activated by cytokines involved in the pathophysiology of rheumatoid arthritis. Areas covered: Clinical trials of tofacitinib have revealed an anti-rheumatic effect of monotherapy and combination therapy with methotrexate (MTX). Post-hoc analysis of those clinical trials and real-world experiences will be reviewed to explore tofacitinib's efficacy and safety. Expert commentary: The efficacy of tofacitinib monotherapy has garnered much attention and has been initiated in a fairly larg...
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research
Abstract BACKGROUND There have been no reports concerning the efficacy of pretransplant herpes zoster (HZ) vaccination following living donor liver transplantation (LDLT). MATERIAL AND METHODS From January 2013 to May 2016, 24 patients age 50 years and older received vaccination of HZ prior to transplantation and underwent LDLT at a single institution. We compared this to the 1-year HZ incidence of unvaccinated recipients (N=180) who underwent LDLT in the same time period. RESULTS For general characteristics, the MELD scores (p
Source: Annals of Transplantation - Category: Transplant Surgery Authors: Tags: Ann Transplant Source Type: research
Abstract Herpes zoster is common in older and immune suppressed persons due to diminished VZV-specific cellular immunity. A recombinant herpes zoster vaccine (RZV) consisting of a single VZV glycoprotein and an adjuvant system stimulates robust and persistent VZV-specific antibody and CD4+ T cell responses in these high-risk populations. VZV-specific immune responses induced by RZV, including the generation of polyfunctional T cells, are driven by the synergistic actions of the components of the vaccine adjuvant system. RZV provides unprecedented protection against herpes zoster in older adults regardless of age a...
Source: Current Opinion in Immunology - Category: Allergy & Immunology Authors: Tags: Curr Opin Immunol Source Type: research
CONCLUSION: RZV is significantly more effective in reducing HZ and PHN incidence in adults ≥60 YOA, compared with ZVL. As anticipated with an adjuvanted vaccine, RZV results in more reactogenicity following immunization. No differences in SAEs were found between RZV and ZVL. PMID: 30982636 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Christine I. Alston1,2 and Richard D. Dix1,2* 1Department of Biology, Viral Immunology Center, Georgia State University, Atlanta, GA, United States 2Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA, United States Suppressor of cytokine signaling (SOCS) proteins provide selective negative feedback to prevent pathogeneses caused by overstimulation of the immune system. Of the eight known SOCS proteins, SOCS1 and SOCS3 are the best studied, and systemic deletion of either gene causes early lethality in mice. Many viruses, including herpesviruses such as herpes simplex virus and cytomega...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Abstract Clinical trials covering the immunogenicity of a vaccine aim to study the longitudinal dynamics of certain immune cells after vaccination. The corresponding immunogenicity datasets are mainly analyzed by the use of statistical (mixed effects) models. This paper proposes the use of mathematical ordinary differential equation (ODE) models, combined with a mixed effects approach. ODE models are capable of translating underlying immunological post vaccination processes into mathematical formulas thereby enabling a testable data analysis. Mixed models include both population-averaged parameters (fixed effects)...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Tags: Continuing Medical Education (CME) Activity Source Type: research
ConclusionThe most advanced phase III clinical applications led to the development of two vaccines containing QS-21 as part of AS, the Herpes Zoster vaccine (HZ/su) (ShingrixTM) which received a license in 2017 from the FDA and a marketing authorization in EU in 2018 and the RTS,S/AS01 vaccine (MosquirixTM) against malaria which was approved by the EMA in 2015 for further implementation in Sub Saharan countries for routine use.Graphical abstract
Source: Phytomedicine - Category: Drugs & Pharmacology Source Type: research
ConclusionThe results of this study demonstrate a high burden of HZ disease in a Brazilian tertiary care hospital in the HZ vaccination era. Awareness of the incidence and comorbidity factors associated with HZ in Latin American countries such as Brazil contribute for adoption and implementation of strategies for immunization in this area.
Source: The Brazilian Journal of Infectious Diseases - Category: Infectious Diseases Source Type: research
ConclusionVaccination against HZ with RZV would be cost-effective compared with no vaccination for the Japanese population aged ≥ 65 years.Trial RegistrationGSK study identifier: HO-16-17837.FundingGlaxoSmithKline Biologicals SA.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research
More News: Herpes | Pharmaceuticals | Shingles (Herpes Zoster) Vaccine | Study | Vaccines | Varicella-Zoster Virus Vaccine